Pages that link to "Q59089053"

The following pages link to Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon (Q59089053):

Displaying 42 items.

• The biology of interferon-alpha and the clinical significance of anti-interferon antibodies (Q30431132) (← links)
• Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis. (Q33270865) (← links)
• Risks and benefits of interferon-alpha in the treatment of hepatitis (Q33496785) (← links)
• The oligosaccharides of glycoproteins: bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties (Q35292620) (← links)
• Core (2'-5')oligoadenylate and the cordycepin analog: inhibitors of Epstein--Barr virus-induced transformation of human lymphocytes in the absence of interferon (Q36377385) (← links)
• The Potential of Interferons in Malignant Disease (Q36561987) (← links)
• Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine (Q37009904) (← links)
• Immunoregulation by naturally occurring and disease-associated autoantibodies : binding to cytokines and their role in regulation of T-cell responses (Q38035778) (← links)
• Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice. (Q39475942) (← links)
• Interferon—Present and Future Prospects (Q40109995) (← links)
• Binding of cytokines to pharmaceutically prepared human immunoglobulin (Q40305824) (← links)
• Clinical toxicity of the interferons. (Q40390091) (← links)
• Interferons for viral hepatitis (Q40399739) (← links)
• Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. (Q40862556) (← links)
• The relevance of pharmacokinetics in the development of biotechnology products (Q41138039) (← links)
• Interferon therapy for non-A, non-B chronic hepatitis (Q42984485) (← links)
• Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report. (Q43039969) (← links)
• Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. (Q43048315) (← links)
• Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. (Q43644002) (← links)
• Detection of autoantibodies to cytokines (Q43942448) (← links)
• Expression in Escherichia coli and purification of the functional feline granulocyte colony-stimulating factor (Q44234389) (← links)
• Cell-mediated cytotoxicity in hepatitis A virus infection (Q44516640) (← links)
• Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection (Q45849818) (← links)
• Assessment of the antigenic response in humans to a recombinant mutant interferon beta (Q46959396) (← links)
• Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α. (Q52564132) (← links)
• Clinical effect of interferon in malignant brain tumours. (Q55488998) (← links)
• Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist (Q58535949) (← links)
• Effects of Interferon-Alpha on Cytomegalovirus Reactivation Syndromes in Renal-Transplant Recipients (Q67297418) (← links)
• The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2) (Q68809345) (← links)
• Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (Q69905224) (← links)
• Induction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferon (Q71629909) (← links)
• Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C (Q72065842) (← links)
• Further studies on clinical trials of interferon in Japan (Q72383951) (← links)
• A radioimmunologic technique to screen for antibodies to α-2 interferon (Q72408921) (← links)
• Antibodies to human leucocyte interferons in cancer patients (Q72542136) (← links)
• Patient with circulating antibodies to alpha-interferon (Q72652571) (← links)
• A radioimmunoassay of human leukocyte interferon using protein a-containing Staphylococcus aureus (Q72656969) (← links)
• Pharmacological Aspects of Clinical Stage 1/ II Trials with Human Beta Interferon in Children (Q72674003) (← links)
• Autoantibodies Against Human Beta Interferon Following Treatment with Interferon (Q72674090) (← links)
• Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta (Q72790094) (← links)
• Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 (Q99710548) (← links)
• Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors (Q106452526) (← links)